Efficacy and safety of Axicabtagene ciloleucel (Axi‐cel) for the treatment of relapse/refractory non‐Hodgkin lymphoma: First real‐world data in Chinese population.
B Background: b Axi-cel was approved by NMPA to treat R/R LBCL adult patients who had received 2 or more prior treatments in 2021 June. Eighty-one patients experienced cytokine release syndrome (CRS) of any grade, and 16 (15.2%) patients occurred grade 3 or higher. The median prior lines of therapy was 2, including 36 (35.6%) patients got >=3 previous treatments and 10 patients had history of ASCT.